Journal
JOURNAL OF PERINATOLOGY
Volume 30, Issue 4, Pages 275-280Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/jp.2009.155
Keywords
nitrite; bronchopulmonary dysplasia; NO CLD trial
Categories
Funding
- National Institutes of Health [U01 HL62514, P50 HL56401, P30 HD26979, MRDDRC P30 HD26979, R01 HL70560, HL62472, HL62868, HL75930, HL 73896]
- General Clinical Research Centers Program [M01 RR00240, M01 RR00084, M01 RR00425, M01 RR001271, M01 RR00064, M01 RR00080]
Ask authors/readers for more resources
Objective: Inhaled nitric oxide (iNO) is a potential new therapy for prevention of bronchopulmonary dysplasia and brain injury in premature infants. This study examined dose-related effects of iNO on NO metabolites as evidence of NO delivery. Study Design: A subset of 102 premature infants in the NO CLD trial, receiving 24 days of iNO (20 p.p.m. decreasing to 2 p.p.m.) or placebo, were analyzed. Tracheal aspirate (TA) and plasma samples collected at enrollment and at intervals during study gas were analyzed for NO metabolites. Result: iNO treatment increased NO metabolites in TA at 20 and 10 p.p.m. (1.7- to 2.3-fold vs control) and in plasma at 20, 10, and 5 p.p.m. (1.6- to 2.3-fold). In post hoc analysis, treated infants with lower metabolite levels at entry had an improved clinical outcome. Conclusion: iNO causes dose-related increases in NO metabolites in the circulation as well as lung fluid, as evidenced by TA analysis, showing NO delivery to these compartments. Journal of Perinatology (2010) 30, 275-280; doi: 10.1038/jp.2009.155; published online 8 October 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available